For more than 20 years, Sharon Campbell, PhD, has been studying Ras, a protein implicated in 30 percent of all cancers. Now she’s on the hunt for alternative ways to shut the protein down.
Kirsten Bryant, PhD, was recently recognized by the Pancreatic Cancer Action Network for her dual role in the fight against pancreatic cancer.
UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic “drivers” of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy. The study, published online August 24 in Nature Genetics, was authored by Michael Gatza, PhD, lead author and post-doctoral research associate; Grace Silva, graduate student; Joel Parker, PhD, director of bioinformatics, UNC Lineberger; Cheng Fan, research associate; and senior author Chuck Perou, PhD, professor of genetics and pathology.
Part of More Than $24.7 Million Awarded in New Grants by the St. Baldrick’s Foundation
An international scientific collaboration led by researchers at UNC has revealed new insights into the unique genetic alterations that contribute to a rare form of kidney cancer.
A substantial number of older patients with limited life expectancy receive routine screenings for prostate, breast, cervical and colorectal cancer even though the procedures are unlikely to benefit them, according to research conducted at the University of North Carolina at Chapel Hill.
UNC Lineberger Comprehensive Cancer Center has awarded nine researchers with Developmental Research Awards to support their work in advancing the fields of clinical/translational and population science cancer research.
A recent article published in the July/August 2014 issue of Health Leaders magazine focuses on some of UNC Lineberger’s strengths that rank it among the nation’s leading cancer centers.
A recent U.S. News & World Report article highlights the nation’s cancer centers, focusing especially on those that the National Cancer Institute has designated as comprehensive cancer centers, citing advantages of patients being seen at or referred to these sites, including advances in technology and collaboration.
Researchers with The Cancer Genome Atlas (TCGA) Research Network have completed the largest, most diverse tumor genetic analysis ever conducted, revealing a new approach to classifying cancers. The work, led by researchers at the UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill and other TCGA sites, not only revamps traditional ideas of how cancers are diagnosed and treated, but could also have a profound impact on the future landscape of drug development.